Diabetes abolish cardioprotective effects of remote ischemic conditioning: evidences and possible mechanisms.
AMP-Activated Protein Kinases
/ genetics
Acetylglucosamine
/ metabolism
Animals
Arginase
/ genetics
Autophagy
Beclin-1
/ genetics
Diabetes Mellitus, Type 2
/ genetics
Gene Expression Regulation
Humans
Ischemic Preconditioning, Myocardial
Myocardial Infarction
/ genetics
Myocardial Reperfusion Injury
/ genetics
Nitric Oxide
/ metabolism
Oxidative Stress
Phosphatidylinositol 3-Kinase
/ genetics
Proto-Oncogene Proteins c-akt
/ genetics
Reactive Oxygen Species
/ metabolism
Signal Transduction
TOR Serine-Threonine Kinases
/ genetics
rho-Associated Kinases
/ genetics
Autophagy
Diabetes
Heart
Oxidative stress
ROCK
Journal
Journal of physiology and biochemistry
ISSN: 1877-8755
Titre abrégé: J Physiol Biochem
Pays: Spain
ID NLM: 9812509
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
29
06
2018
accepted:
24
01
2019
pubmed:
8
2
2019
medline:
30
3
2019
entrez:
8
2
2019
Statut:
ppublish
Résumé
Diabetes mellitus significantly hampers the development of cardioprotective response to remote pre/post/perconditioning stimuli by impairing the activation of cardioprotective signaling pathways. Among the different pathways, the impairment in O-linked β-N-acetylglucosamine (O-GlcNAc) signaling and release of cardioprotective humoral factor may contribute in attenuating remote preconditioning-induced cardioprotection. Moreover, the failure to phosphorylate extracellular signal related kinase (ERK), phosphoinositide-3-kinase (PI3K), and AKT along with up-regulation of mechanistic target of rapamycin (mTOR) and decrease in autophagy may also attenuate remote preconditioning-induced cardioprotection. Remote perconditioning stimulus also fails to phosphorylate AKT kinase in diabetic heart. In addition, diabetes may increase the oxidative stress, reactive oxygen species (ROS) production, decrease the beclin expression, and inhibit autophagy to attenuate remote perconditioning-induced cardioprotection. Moreover, diabetes-induced increase in the Rho-associated kinase (ROCK) activity, decrease in the arginase activity, and reduction in nitric oxide (NO) bioavailability may also contribute in decreasing remote perconditioning-induced cardioprotection. Diabetes may reduce the phosphorylation of adenosine 5'-monophosphate activated protein kinase (AMPKα) and increase the phosphorylation of mTOR to attenuate cardioprotection of remote postconditioning. The present review describes the role of diabetes in attenuating remote ischemic conditioning-induced cardioprotection along with the possible mechanisms.
Identifiants
pubmed: 30729392
doi: 10.1007/s13105-019-00664-w
pii: 10.1007/s13105-019-00664-w
doi:
Substances chimiques
Beclin-1
0
Reactive Oxygen Species
0
Nitric Oxide
31C4KY9ESH
MTOR protein, human
EC 2.7.1.1
Phosphatidylinositol 3-Kinase
EC 2.7.1.137
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
rho-Associated Kinases
EC 2.7.11.1
AMP-Activated Protein Kinases
EC 2.7.11.31
PRKAA1 protein, human
EC 2.7.11.31
Arginase
EC 3.5.3.1
Acetylglucosamine
V956696549
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-28Références
Circulation. 2002 Jan 22;105(3):334-40
pubmed: 11804989
Circulation. 2002 Dec 3;106(23):2881-3
pubmed: 12460865
Cardiovasc Res. 2004 Feb 15;61(3):448-60
pubmed: 14962476
Cardiovasc Res. 2004 Feb 15;61(3):548-58
pubmed: 14962485
Eur J Pharmacol. 2005 May 16;515(1-3):142-9
pubmed: 15894305
J Am Coll Cardiol. 2006 Jun 6;47(11):2277-82
pubmed: 16750696
Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1883-90
pubmed: 17172279
Circulation. 2007 Apr 24;115(16):2178-87
pubmed: 17420349
Acta Diabetol. 2008 Mar;45(1):41-6
pubmed: 17924055
Diabetes. 2008 Apr;57(4):945-57
pubmed: 18174523
Mol Cell Biochem. 2008 Aug;315(1-2):195-201
pubmed: 18528635
J Card Surg. 2010 Jan-Feb;25(1):127-34
pubmed: 19549044
Circ Res. 2009 Dec 4;105(12):1223-31
pubmed: 19850943
Lancet. 2010 Feb 27;375(9716):727-34
pubmed: 20189026
Basic Res Cardiol. 2010 Sep;105(5):651-5
pubmed: 20449597
J Cardiothorac Surg. 2011 Mar 23;6:34
pubmed: 21426585
Drugs Aging. 2011 May 1;28(5):331-43
pubmed: 21542657
Autophagy. 2012 Apr;8(4):577-92
pubmed: 22498478
Basic Res Cardiol. 2012 Sep;107(5):285
pubmed: 22821347
J Physiol Biochem. 2013 Jun;69(2):165-75
pubmed: 22941749
J Pathol. 2013 Jan;229(2):232-41
pubmed: 23011912
Cardiovasc Res. 2013 Feb 1;97(2):369-78
pubmed: 23201773
J Cell Mol Med. 2013 Jan;17(1):181-91
pubmed: 23305039
J Thorac Cardiovasc Surg. 2014 Jan;147(1):376-82
pubmed: 23465551
Clinics (Sao Paulo). 2013;68(2):263-8
pubmed: 23525325
Circulation. 2013 Nov 5;128(19):2132-44
pubmed: 24008870
JACC Cardiovasc Interv. 2013 Oct;6(10):1055-63
pubmed: 24156966
Acta Physiol (Oxf). 2014 Mar;210(3):546-64
pubmed: 24286628
J Biol Chem. 2014 Feb 14;289(7):4145-60
pubmed: 24371138
PLoS One. 2014 Jan 23;9(1):e86838
pubmed: 24466263
PLoS One. 2014 Aug 20;9(8):e104731
pubmed: 25140754
Eur J Pharmacol. 2015 Jan 5;746:317-32
pubmed: 25176179
Pharmacol Rev. 2014 Oct;66(4):1142-74
pubmed: 25261534
Invest Ophthalmol Vis Sci. 2014 Oct 02;55(11):7126-36
pubmed: 25277230
PLoS One. 2014 Oct 27;9(10):e111291
pubmed: 25347774
Cardiovasc Diagn Ther. 2014 Oct;4(5):383-96
pubmed: 25414825
Dis Model Mech. 2014 Dec;7(12):1321-33
pubmed: 25481012
Med Gas Res. 2014 Dec 12;4(1):20
pubmed: 25525500
Int J Clin Exp Med. 2014 Nov 15;7(11):4107-14
pubmed: 25550920
J Cardiovasc Pharmacol Ther. 2015 Jul;20(4):357-69
pubmed: 25627214
J Cell Mol Med. 2015 Jun;19(6):1174-82
pubmed: 25688987
Curr Drug Targets. 2015;16(8):904-11
pubmed: 25915487
N Engl J Med. 2015 Oct 8;373(15):1408-17
pubmed: 26436207
N Engl J Med. 2015 Oct 8;373(15):1397-407
pubmed: 26436208
Cardiovasc Diabetol. 2015 Nov 18;14:151
pubmed: 26581389
Diabetes Metab J. 2015 Dec;39(6):461-7
pubmed: 26706915
Naunyn Schmiedebergs Arch Pharmacol. 2016 Aug;389(8):887-96
pubmed: 27118661
Am J Physiol Heart Circ Physiol. 2016 Aug 1;311(2):H364-70
pubmed: 27288436
J Cardiovasc Pharmacol Ther. 2017 Mar;22(2):112-121
pubmed: 27459954
BMC Cardiovasc Disord. 2016 Oct 11;16(1):193
pubmed: 27724862
Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):117-126
pubmed: 27752734
PLoS One. 2017 Jan 27;12(1):e0170729
pubmed: 28129389
Korean J Physiol Pharmacol. 2017 Mar;21(2):145-152
pubmed: 28280407
Int J Mol Sci. 2017 Mar 11;18(3):
pubmed: 28287478
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):302-309
pubmed: 28381115
Cardiovasc Diabetol. 2017 Apr 26;16(1):57
pubmed: 28446231
Eur J Pharmacol. 2017 Nov 5;814:9-17
pubmed: 28755986
Basic Res Cardiol. 2017 Nov 15;113(1):2
pubmed: 29143177
Int J Cardiol. 2018 Feb 1;252:24-30
pubmed: 29249435
Pediatr Cardiol. 2018 Mar;39(3):617-626
pubmed: 29302715
Acta Cir Bras. 2018 May;33(5):396-407
pubmed: 29924210
Korean J Physiol Pharmacol. 2018 Sep;22(5):467-479
pubmed: 30181694
J Cardiovasc Pharmacol. 2019 Feb;73(2):63-69
pubmed: 30422893
JAMA. 1979 May 11;241(19):2035-8
pubmed: 430798
Circulation. 1993 Mar;87(3):893-9
pubmed: 7680290
Circulation. 1996 Nov 1;94(9):2193-200
pubmed: 8901671
Circulation. 1997 Jul 1;96(1):29-32
pubmed: 9236412
Circulation. 1997 Sep 2;96(5):1641-6
pubmed: 9315559